Obinutuzumab: its use in the management of chronic lymphocytic leukemia

Bibliography

• Dameshek W. Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967;29(4):566-84
   Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975-80
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009;114(10):2044-50
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC; Lyon: 2008
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997-1007
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101(3):949-54
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000;51(6):634-41
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101(3):1045-52
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29(26):3559-66
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181(1):822-32
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183(1):749-58
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28(10):1749-55
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117(24):6450-8
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood 2013;122(21):Abstract 528
   Google Scholar
• Illidge T, Cheadle EJ, Donaghy C, Honeychurch J. Update on obinutuzumab in the treatment of B-cell malignancies. Expert Opin Biol Ther 2014;14(10):1507-17
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol 2014;192(12):5618-24
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013;122(20):3482-91
   PubMed Web of Science ®Google Scholar
• Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12(3):343-51
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118(2):358-67
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393-402
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119(22):5118-25
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014;124(14):2196-202
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N Engl J Med 2014;370(12):1101-10
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 2013;27(5):1172-4
   PubMed Web of Science ®Google Scholar
• Goede V, Engelke A, Fischer K, et al. Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. ASH annual meeting Abstract 3327 2014, San Franciso, CA 2014
   Google Scholar
• Obinutuzumab breaks through to FDA approval. Cancer Discov 2014;4(1):OF6
   Google Scholar
• National Comprehensive Cancer Network. Non-Hodgkin’s Lymphomas (version 5.2014). Available from: http://www.nccn.org [Last Accessed 17 December 2014]
   Google Scholar
• Brown JR, O’Brien S, Kingsley CD, et al. Obinutuzumab (G) plus fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood 2015
   Google Scholar
• Bosch F, Illmer T, Turgut M, et al. Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH annual meeting abstract 3345 2014, San Franciso, CA 2014
   Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213-23
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014;123(12):1957-60
   PubMed Web of Science ®Google Scholar
• Bojarczuk K, Siernicka M, Dwojak M, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 2014;28(5):1163-7
   PubMed Web of Science ®Google Scholar
• Davis C, Stepanchick E, Syed K, et al. Effects of Ibrutinib on Rituximab and GA-101 INduced Antibody-Dependent Cell Cytotoxicity (ADCC) in Lymphoma Cells in Vitro. ASH annual meeting abstract 625 2014, San Franciso, CA 2014
   Google Scholar
• Herter S, Sagiv-Barfi I, Chester C, et al. Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo. ASH annual meeting abstract 1765 2014, San Franciso, CA 2014
   Google Scholar
• Ysebaert L, Klein C, Quillet-Mary A. Ibrutinib Exposure and B-cell Depletion INduced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is there a Rationale for Combination Studies. ASH annual meeting abstract 1980 2014, San Franciso, CA 2014
   Google Scholar
• Herter S, Palazzo A, Bacac M, et al. The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated by Obinutuzumab (GA101) and Rituximab. ASH annual meeting abstract 3342 2014.
   Google Scholar
• Seymour JF, Davids MS, Pagel JM, et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013;122(21):Abstract 872
   Google Scholar
• Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79(11):2981-9
   Google Scholar
• Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82(6):1820-8
   PubMed Web of Science ®Google Scholar
• Ma S, Seymour J, Lanasa M, et al. ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. J Clin Oncol 2014;32(5s):abstract 7013
   Google Scholar
• Flinn I, Brunvand M, Dyer MJ, et al. Preliminary Results of a Phase 1b Study (GP28331) COmbining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or previously Untreated Chronic Lymphocytic Leukemia. ASH annual meeting abstract 4687 2014.
   Google Scholar
• Freeman CL, Dixon M, Houghton R, et al. Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset. ASH annual meeting abstract 3339 2014.
   Google Scholar
• Freeman CL, Morschhauser F, Sehn LH, et al. Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR). ASH annual meeting abstract 4674 2014.
   Google Scholar
• Green MR, Williams ME, Willey J, et al. First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents. ASH annual meeting abstract 4676 2014.
   Google Scholar